PB2230: EFFICACY AND SAFETY OF SINOPHARM VACCINE FOR SARS-COV-2 AND BREAKTHROUGH INFECTIONS IN IRANIAN PATIENTS WITH HEMOGLOBINOPATHIES: A PRELIMINARY REPORT

MLA

M. Karimi, et al. “Pb2230: Efficacy and Safety of Sinopharm Vaccine for Sars-Cov-2 and Breakthrough Infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.” HemaSphere, vol. 6, June 2022, pp. 2100–01. EBSCOhost, https://doi.org/10.1097/01.HS9.0000851748.27564.18.

APA

M. Karimi, T. Zarei, S. Haghpanah, A. Azarkeivan, M. Naderi, S. Matin, A. Bazrafshan, Z. Zahedi, A. Shirkavand, P. Pishdad, & V. De Sanctis. (2022). Pb2230: Efficacy and Safety of Sinopharm Vaccine for Sars-Cov-2 and Breakthrough Infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report. HemaSphere, 6, 2100–2101. https://doi.org/10.1097/01.HS9.0000851748.27564.18

Chicago

M. Karimi, T. Zarei, S. Haghpanah, A. Azarkeivan, M. Naderi, S. Matin, A. Bazrafshan, et al. 2022. “Pb2230: Efficacy and Safety of Sinopharm Vaccine for Sars-Cov-2 and Breakthrough Infections in Iranian Patients with Hemoglobinopathies: A Preliminary Report.” HemaSphere 6 (June): 2100–2101. doi:10.1097/01.HS9.0000851748.27564.18.